Table 5.
Pathway enrichment analysis using EnrichR identified as differentially expressed in ileal or right colon mucosa in BAD compared with IBS-D without ABAM
| Term | Overlap | Padj value | OR | Combined score | Genes | DE expression | Confirmation of category |
|---|---|---|---|---|---|---|---|
| Terminal ileum mucosa | |||||||
| Complement and coagulation cascades | 1/79 | 0.0118 | 255.4 | 1236.8 | C6 | Up | KEGG_2019_Human |
| Right colon mucosa | |||||||
| Mucin type O-glycan biosynthesis | 1/31 | 0.0125 | 133.1 | 623.1 | GALNT15 | Down | KEGG_2019_Human |
| O-glycan processing | 1/65 | 0.0363 | 62.3 | 245.7 | GALNT15 | Down | GO_Biological _Process |
| Cytokine-cytokine receptor interaction | 3/294 | 0.0224 | 14.5 | 91.4 |
CCL25
CXCL5 IL1RN |
Up | KEGG_2019_Human |
ABAM, abnormal bile acid metabolism; BAD, bile acid diarrhoea; DE, differential expression; IBS-D, irritable bowel syndrome with diarrhoea; Padj, adjusted p.